Serious long-term complications include cardiovascular disease (doubled risk), chronic renal failure, retinal damage (which can lead to gangrene, and possibly to amputation.
There is no known preventive measure which can be taken against type 1 diabetes; it is about 10% of diabetes mellitus cases in North America have diabetes) and family history (type 2 is much more common in those with close relatives who have had it).
There are numerous theories as to the exact cause and mechanism in type 2 diabetes.
The average glucose level for the type 1 patient should be as close to normal (80–120 mg/dl, 4–6 mmol/l) as is safely possible.
However, low levels of blood glucose, called hypoglycemia, may lead to seizures or episodes of unconsciousness and absolutely must be treated immediately, via emergency high-glucose gell placed in the patient's mouth or an injection of glucagon.
Beyond these two types, there is no agreed-upon standard nomenclature.
Type 2 diabetes mellitusType 2 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas, leading to a deficiency of insulin.
Likewise, the term "type 2 diabetes" has replaced several former terms, including adult-onset diabetes, obesity-related diabetes, and non-insulin-dependent diabetes (NIDDM).
Obesity is found in approximately 55% of patients diagnosed with type 2 diabetes.
Non-insulin treatments, such as monoclonal antibodies and stem-cell based therapies, are effective in animal models but have not yet completed clinical trials in humans.
The injections by a syringe, insulin pump, or insulin pen deliver insulin, which is a basic treatment of type 1 diabetes.
However, treatment is burdensome for patients, insulin is replaced in a non-physiological manner, and this approach is therefore far from ideal.
The defective responsiveness of body tissues to insulin almost certainly involves the insulin receptor in cell membranes...

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p
Amylin Pharmaceuticals, Inc., , Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration recently indicated that the ongoing extension of the DURATION-1 study is appropriate to use as the basis for demonstrating comparability between intermediate-scale clinical trial material made in Alkermes' manufacturing facility, and commercial-scale drug product ...
Copyright © 2004 by www-DiabetesCare.com All Rights Reserved.